BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
BI 655066/ABBV-066 (Risankizumab) Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis (UltIMMa-1)
Sponsor: AbbVie
This PHASE3 trial investigates Psoriasis and is currently completed. AbbVie leads this study, which shows 11 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE3
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Jun 2018 — Jul 2019 [monthly]
Completed PHASE3
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Aug 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
-
May 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Feb 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.